期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

C8092A及-673C>T单核苷酸多态性与非小细胞肺癌顺铂化疗疗效的关系

The Relationship of C8092A,-673C >T Single Nucleoside Polymorphism with the Response of Cisplatin-based Chemotherapy for Patients with NSCLC
原文传递
导出
摘要 [目的]探讨C8092A、-673C>T单核苷酸多态性对顺铂为基础化疗非小细胞肺癌(NSCLC)患者疗效的影响。[方法]采用多聚酶链反应—限制片段长度多态性(PCR-RFLP)法对NSCLC患者进行基因分型,并分析基因多态性与化疗疗效的相关性。[结果]C8092A野生型(CC)与携带A等位基因(CA+AA)客观有效率无统计学差异(24.1%vs25.0%,P>0.05),野生型的疾病控制率与携带A等位基因差异无统计学意义(82.8%vs68.8%,P>0.05);野生型无进展生存期(PFS)223.8d,携带A等位基因者219.5d(P>0.05)。-673C>T野生型(CC)与携带T等位基因型(CT+TT)客观有效率无统计学差异(25.0%vs23.8%,P>0.05);携带T等位基因疾病控制率与野生型患者差异无统计学意义(81.0%vs72.5%,P>0.05);野生型PFS221.4d,携带T等位基因型PFS233.5d(P>0.05)。[结论]以顺铂为基础化疗NSCLC患者疗效与C8092A、-673C>T单核苷酸多态性(SNP)无关。
作者 华之卉 房文铮 赵忠全 解方为 欧阳学农 柳德灵 宋洪涛
机构地区 南京军区福州总医院 沈阳药科大学药学院
出处 《肿瘤学杂志》 CAS 2011年第9期662-665,共4页 Journal of Chinese Oncology
关键词 癌 非小细胞肺 顺铂 单核苷酸多态性 C8092A -673C>T
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Jemal A,Murray T,Ward E,et al.Cancer statistics,2005[J].CA Cancer J Clin,2005,55(1):10-30.
  • 2Okuda K,Sasaki H,Hikosaka Y,et al.Excision repair cross complementation group1polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer[J].J Surg Res,2011,168(2):206-212.
  • 3Zhou W,Gurubhagavatula S,Liu G,et al.Excision repair cross complementation group1polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy[J].Clin Cancer Res,2004,10(15):4939-4943.
  • 4Takenaka T,Yano T,Kiyohara C,et al.Effects of exci-sion repair cross-complementation group1(ERCC1)single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients[J].Lung Cancer,2010,67(1):101-107.
  • 5Kalikaki A,Kanaki M,Vassalou H,et al.DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer[J].Clin Lung Can-cer,2009,10(2):118-123.
  • 6Li F,Sun X,Sun N,et al.Association between polymor-phisms of ERCC1and XPD and clinical response to plati-num-based chemotherapy in advanced non-small cell lung cancer[J].Am J Clin Oncol,2010,33(5):489-494.
  • 7袁芃,缪小平,张雪梅,王中华,谭文,孙燕,张湘茹,徐兵河,林东昕.DNA损伤修复基因XRCC1和XPD遗传多态与晚期非小细胞肺癌对铂类药物的敏感性[J].中华肿瘤杂志,2006,28(3):196-199. 被引量：39
  • 8Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst,2000,92(3):205-216.
  • 9涂向东,江清华,兰风华.三种简易提取全血基因组DNA方法的比较[J].中国实验诊断学,2006,10(3):264-266. 被引量：29
  • 10Yin M,Yan J,Voutsina A,et al.No evidence of an asso-ciation of ERCC1and ERCC2polymorphisms with clini-cal outcomes of platinum-based chemotherapies in non-small cell lung cancer:a meta-analysis[J].Lung Cancer,2011,72(3):370-377.

二级参考文献17

  • 1Kelland LB. Precllnical perspectives on platinum resistance. Drugs,2000, 59 Suppl 4:1-8.
  • 2Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ nonsmall cell lung cancer: a phase Ⅲ randomized trial. Lung Cancer,2003, 41: 321-331.
  • 3Aloyz B, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational rear by the TF Ⅱ H subunit XPD.Cancer Res, 2002, 62: 5457-5462.
  • 4Lunn BM, Langlois BG, Hsieh LL, et al. XBCCI polymorphisms:effects on aflatoxin BI-DNA adducts and glycophorin A variant frequency. Cancer Res, 1999, 59 : 2557-2561.
  • 5Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet danmage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis, 2002, 23: 295-299.
  • 6Xring D, Qi J, Miao X, et al. Polymorphisms of DNA repair genes XRCCI and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer,2002, 100: 600-605.
  • 7Roses AD. Pharmacogenetics and the practice of medicine. Nature,2000, 405 : 857-865.
  • 8Bosell B, Lord BY, Talon M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer, 2002, 38 :217-227.
  • 9Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis, 2001 :22:593-597.
  • 10Wei Q, Frazier ML, I~vin B. DNA Repair: a double-edged sword.J Natl Cancer Inst, 2000, 92: 440-441.

共引文献66

肿瘤学杂志
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部